The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer

Radiotherapy can convert malignant cells into an in situ anticancer vaccine, but is often inadequate at generating sufficient pro-inflammatory signals to optimally activate innate and adaptive immune responses. Topical imiquimod is a powerful pro-inflammatory agent with clinical activity against sup...

Descripción completa

Detalles Bibliográficos
Autores principales: Demaria, Sandra, Vanpouille-Box, Claire, Formenti, Silvia C, Adams, Sylvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3881106/
https://www.ncbi.nlm.nih.gov/pubmed/24404422
http://dx.doi.org/10.4161/onci.25997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3881106/
https://www.ncbi.nlm.nih.gov/pubmed/24404422
http://dx.doi.org/10.4161/onci.25997

Ejemplares similares